JP2019505541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505541A5 JP2019505541A5 JP2018543101A JP2018543101A JP2019505541A5 JP 2019505541 A5 JP2019505541 A5 JP 2019505541A5 JP 2018543101 A JP2018543101 A JP 2018543101A JP 2018543101 A JP2018543101 A JP 2018543101A JP 2019505541 A5 JP2019505541 A5 JP 2019505541A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- pharmaceutically acceptable
- solvate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112227A JP7289876B2 (ja) | 2016-02-19 | 2021-07-06 | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297522P | 2016-02-19 | 2016-02-19 | |
| US62/297,522 | 2016-02-19 | ||
| PCT/IB2017/000237 WO2017141116A1 (en) | 2016-02-19 | 2017-02-17 | Carboxamide derivatives useful as rsk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112227A Division JP7289876B2 (ja) | 2016-02-19 | 2021-07-06 | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505541A JP2019505541A (ja) | 2019-02-28 |
| JP2019505541A5 true JP2019505541A5 (enExample) | 2020-03-26 |
| JP6912486B2 JP6912486B2 (ja) | 2021-08-04 |
Family
ID=59625645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543101A Active JP6912486B2 (ja) | 2016-02-19 | 2017-02-17 | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 |
| JP2021112227A Active JP7289876B2 (ja) | 2016-02-19 | 2021-07-06 | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112227A Active JP7289876B2 (ja) | 2016-02-19 | 2021-07-06 | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9771366B2 (enExample) |
| EP (2) | EP3416964B1 (enExample) |
| JP (2) | JP6912486B2 (enExample) |
| KR (1) | KR102746242B1 (enExample) |
| CN (2) | CN109071542B (enExample) |
| AU (1) | AU2017220738B2 (enExample) |
| CO (1) | CO2018008846A2 (enExample) |
| DK (1) | DK3416964T3 (enExample) |
| ES (1) | ES2858753T3 (enExample) |
| IL (1) | IL261170B (enExample) |
| MX (1) | MX376974B (enExample) |
| PL (1) | PL3416964T3 (enExample) |
| PT (1) | PT3416964T (enExample) |
| WO (1) | WO2017141116A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2016150884A1 (en) | 2015-03-20 | 2016-09-29 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| CA2990521C (en) | 2015-07-07 | 2023-10-10 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| US11918687B2 (en) | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| WO2017141116A1 (en) * | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
| AU2018300272B2 (en) | 2017-07-14 | 2024-09-19 | Orbsen Therapeutics Limited | CD39 stromal stem cells methods of isolation and use |
| BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| CN109847063B (zh) * | 2018-12-26 | 2023-02-28 | 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） | Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用 |
| CN109438403A (zh) * | 2018-12-28 | 2019-03-08 | 凯瑞斯德生化(苏州)有限公司 | 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法 |
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
| TW202307005A (zh) * | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
| SMT202500447T1 (it) | 2021-11-02 | 2026-01-12 | Flare Therapeutics Inc | Agonisti inversi di pparg e loro usi |
| US20260193283A1 (en) * | 2022-06-07 | 2026-07-09 | Kinoteck Therapeutics Co., Ltd. | Carboxamide derivative having rsk inhibitory effect, pharmaceutical composition comprising same, and use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| JP2001501946A (ja) | 1996-10-08 | 2001-02-13 | イーライ・リリー・アンド・カンパニー | 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| EP1495016A2 (en) * | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CA2881078C (en) * | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| CA2690410C (en) * | 2007-06-12 | 2015-09-29 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
| NZ583689A (en) | 2007-09-14 | 2012-04-27 | Univ Michigan | F1f0-atpase inhibitors and related methods |
| GB0718870D0 (en) | 2007-09-27 | 2007-11-07 | Univ Dundee | Modulation of RSK |
| WO2011071725A1 (en) * | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
| WO2013181742A1 (en) | 2012-06-04 | 2013-12-12 | Phoenix Molecular Diagnostics Ltd. | Methods of inhibiting rsk for treatment of breast cancer |
| EP2943485B1 (en) * | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| CN103724251B (zh) * | 2014-01-18 | 2015-07-22 | 福州大学 | 一种靶向stat3的小分子化合物及其制备方法和应用 |
| CA2944610C (en) | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| WO2017141116A1 (en) | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
-
2017
- 2017-02-17 WO PCT/IB2017/000237 patent/WO2017141116A1/en not_active Ceased
- 2017-02-17 JP JP2018543101A patent/JP6912486B2/ja active Active
- 2017-02-17 CN CN201780024735.XA patent/CN109071542B/zh active Active
- 2017-02-17 PL PL17752742T patent/PL3416964T3/pl unknown
- 2017-02-17 EP EP17752742.1A patent/EP3416964B1/en active Active
- 2017-02-17 CN CN202110838177.9A patent/CN113620950A/zh active Pending
- 2017-02-17 AU AU2017220738A patent/AU2017220738B2/en active Active
- 2017-02-17 PT PT177527421T patent/PT3416964T/pt unknown
- 2017-02-17 KR KR1020187027085A patent/KR102746242B1/ko active Active
- 2017-02-17 ES ES17752742T patent/ES2858753T3/es active Active
- 2017-02-17 US US15/436,587 patent/US9771366B2/en active Active
- 2017-02-17 DK DK17752742.1T patent/DK3416964T3/da active
- 2017-02-17 EP EP20211105.0A patent/EP3848373A1/en not_active Withdrawn
- 2017-02-17 MX MX2018010028A patent/MX376974B/es active IP Right Grant
- 2017-02-17 US US16/077,029 patent/US10758530B2/en active Active
- 2017-07-31 US US15/665,181 patent/US10081632B2/en active Active
-
2018
- 2018-08-15 IL IL261170A patent/IL261170B/en unknown
- 2018-08-24 CO CONC2018/0008846A patent/CO2018008846A2/es unknown
-
2020
- 2020-06-30 US US16/917,595 patent/US20210186961A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112227A patent/JP7289876B2/ja active Active